Online inquiry

IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11642MR)

This product GTTS-WQ11642MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets LAG3&PDCD1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002286.6; NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3902; 5133
UniProt ID P18627; Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11642MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3135MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA APT070
GTTS-WQ8690MR IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA HuMax-TF
GTTS-WQ12141MR IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MORAb-004
GTTS-WQ7933MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GSK-3359609
GTTS-WQ9574MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ6909MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ENB-0040
GTTS-WQ9548MR IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA J6M0
GTTS-WQ4277MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BIIB-033
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW